Mycenax Biotech Inc. Statistics
Mycenax Biotech Inc. (4726) Stock Statistics & Valuation Metrics
Total Valuation
Mycenax Biotech Inc. has a market cap or net worth of TWD 4.29B. The enterprise value is TWD 6.16B.
- Market Cap
- TWD 4.29B
- Enterprise Value
- TWD 6.16B
Share Statistics
Mycenax Biotech Inc. has 207,041,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 207,041,800
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Mycenax Biotech Inc.’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -14.94%.
- Return on Equity (ROE)
- -0.28
- Return on Assets (ROA)
- -0.14
- Return on Invested Capital (ROIC)
- -14.94%
- Return on Capital Employed (ROCE)
- -0.19
- Revenue Per Employee
- 1.91M
- Profits Per Employee
- -1.16M
- Employee Count
- 387
- Asset Turnover
- 0.23
- Inventory Turnover
- 6.94
Valuation Ratios
The current PE Ratio of Mycenax Biotech Inc. is -12.43. Mycenax Biotech Inc.’s PEG ratio is -0.47.
- PE Ratio
- -12.43
- PS Ratio
- 5.84
- PB Ratio
- 3.38
- Price to FCF
- -212.24
- Price to Operating Cash Flow
- 38.44
- PEG Ratio
- -0.47
Income Statement
In the last 12 months, Mycenax Biotech Inc. had revenue of 740.24M and earned -448.63M in profits. Earnings per share was -2.17.
- Revenue
- 740.24M
- Gross Profit
- -181.41M
- Operating Income
- -403.84M
- Pretax Income
- -454.11M
- Net Income
- -448.63M
- EBITDA
- -119.51M
- Earnings Per Share (EPS)
- -2.17
Cash Flow
In the last 12 months, operating cash flow was 123.94M and capital expenditures -146.38M, giving a free cash flow of -22.44M billion.
- Operating Cash Flow
- 123.94M
- Free Cash Flow
- -22.44M
- Free Cash Flow per Share
- -0.11
Dividends & Yields
Mycenax Biotech Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -0.52%
- Earnings Yield
- -8.80%
Stock Price Statistics
- Beta
- 0.39
- 52-Week Price Change
- -36.50%
- 50-Day Moving Average
- 22.89
- 200-Day Moving Average
- 26.99
- Relative Strength Index (RSI)
- 22.40
- Average Volume (3m)
- 119.75K
Important Dates
Mycenax Biotech Inc. upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 12, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Mycenax Biotech Inc. as a current ratio of 0.55, with Debt / Equity ratio of 67.03%
- Current Ratio
- 0.55
- Quick Ratio
- 0.43
- Debt to Market Cap
- 0.14
- Net Debt to EBITDA
- -7.09
- Interest Coverage Ratio
- -11.99
Taxes
In the past 12 months, Mycenax Biotech Inc. has paid -5.48M in taxes.
- Income Tax
- -5.48M
- Effective Tax Rate
- 0.01
Enterprise Valuation
Mycenax Biotech Inc. EV to EBITDA ratio is -46.74, with an EV/FCF ratio of -231.67.
- EV to Sales
- 6.37
- EV to EBITDA
- -46.74
- EV to Free Cash Flow
- -231.67
- EV to Operating Cash Flow
- 41.94
Balance Sheet
Mycenax Biotech Inc. has TWD 264.94M in cash and marketable securities with TWD 1.12B in debt, giving a net cash position of -TWD 859.34M billion.
- Cash & Marketable Securities
- TWD 264.94M
- Total Debt
- TWD 1.12B
- Net Cash
- -TWD 859.34M
- Net Cash Per Share
- -TWD 4.15
- Tangible Book Value Per Share
- TWD 6.59
Margins
Gross margin is -17.57%, with operating margin of -43.43%, and net profit margin of -46.81%.
- Gross Margin
- -17.57%
- Operating Margin
- -43.43%
- Pretax Margin
- -47.77%
- Net Profit Margin
- -46.81%
- EBITDA Margin
- -13.63%
- EBIT Margin
- -42.98%
Analyst Forecast
The average price target for Mycenax Biotech Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 12.16%
- EPS Growth Forecast
- 23.20%
